The overall hemostasis potential: A laboratory tool for the investigation of global hemostasis

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 7, 2010, Pages 772-779

  Antovic, Aleksandra ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

Global haemostatic assay; hypercoagulability; Overall Haemostatic Potential (OHP)

Indexed keywords

CALCIUM; FIBRIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ANTICOAGULANT THERAPY; BLOOD CLOTTING; DIABETES MELLITUS; FIBRINOLYSIS; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HYPERCOAGULABILITY; ISCHEMIC HEART DISEASE; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOPHILIA; VASCULAR SURGERY;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; FACTOR VIIA; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; THROMBOSIS;

EID: 78049240048     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1265294     Document Type: Review

References (36)

1. Brummel K E., Paradis S G., Butenas S, Mann K G. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002 100 (1) 148-152
2. Mann K G., Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003 1 (7) 1504-1514
3. Erban S B., Kinman J L., Schwartz J S. Routine use of the prothrombin and partial thromboplastin times. JAMA 1989 262 (17) 2428-2432
4. Kitchen S, Cartwright I, Woods T A., Jennings I, Preston F E. Lipid composition of seven APTT reagents in relation to heparin sensitivity. Br J Haematol 1999 106 (3) 801-808
5. Ray M J. An artefact related to the ratio of sample volume to the blood collection vial size which effects the APTTs of specimens taken to monitor heparin therapy. Thromb Haemost 1991 66 (3) 387-388
6. Hillarp A, Egberg N, Nordin G, Stigendal L, Fagerberg I, Lindahl T L. Local INR calibration of the Owren type prothrombin assay greatly improves the intra- and interlaboratory variation. A three-year follow-up from the Swedish national external quality assessment scheme. Thromb Haemost 2004 91 (2) 300-307
7. Hemker H C., Giesen P, AlDieri R et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002 32 (5-6) 249-253
8. Sørensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003 1 (3) 551-558
9. Shima M, Matsumoto T, Fukuda K et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost 2002 87 (3) 436-441
10. Smith A A., Jacobson L J., Miller B I., Hathaway W E., Manco-Johnson M J. A new euglobulin clot lysis assay for global fibrinolysis. Thromb Res 2003 112 (56) 329-337
11. He S, Bremme K, Blombäck M. A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results. Thromb Res 1999 96 (2) 145-156
12. He S, Antovic A, Blombäck M. A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work. Thromb Res 2001 103 (5) 355-361
13. Antovic A, Blombäck M, Sten-Linder M, Petrini P, Holmström M, He S. Possibility of detecting different hypocoagulable states with a modifiable global assay of overall haemostasis potential in plasma. Blood Coagul Fibrinolysis 2005 16 (8) 585-596
14. Antovic A. Determination of Overall Hemostasis Potential and Fibrin Gel Permeability: Method Development and Application in Research and in Clinical Materials [PhD thesis]. Stockholm, Sweden Karolinska Institute 2004
15. Antovic J P., Yngen M, Ostenson C G. et al. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications. Blood Coagul Fibrinolysis 2003 14 (6) 551-556
16. Antovic J P., Rafik Hamad R, Antovic A, Blombäck M, Bremme K. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation? Thromb Haemost 2002 88 (4) 644-647
17. Anzej S, Bozic M, Antovic A et al. Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia. Thromb Res 2007 120 (1) 39-46
18. Rooth E, Wallen H, Antovic A et al. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul Fibrinolysis 2007 18 (4) 365-370
19. Antovic A, Blombäck M, Bremme K, Van Rooijen M, He S. Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance. J Thromb Haemost 2003 1 (12) 2531-2535
20. Andresen M S., Iversen N, Abildgaard U. Overall haemostasis potential assays performed in thrombophilic plasma: the effect of preactivating protein C and antithrombin. Thromb Res 2002 108 (5-6) 323-328
21. Andresen M S., Abildgaard U, Liestøl S et al. The ability of three global plasma assays to recognize thrombophilia. Thromb Res 2004 113 (6) 411-417
22. Andresen M S., Abildgaard U. Coagulation Inhibitor Potential: a study of assay variables. Thromb Res 2005 115 (6) 519-526
23. Andresen M S., Eilertsen A L., Abildgaard U, Sandset P M. Hormone therapy and raloxifene reduce the coagulation inhibitor potential. Blood Coagul Fibrinolysis 2007 18 (5) 455-460
24. Antovic J P., Antovic A, Sten-Linder M, Wramsby M, Blombäck M. Overall hemostatic potential (OHP) assaya possible tool for determination of prothrombotic pattern in FXII deficiency. J Thromb Haemost 2004 2 (11) 2058-2060
25. Curnow J L., Morel-Kopp M C., Roddie C, Aboud M, Ward C M. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J Thromb Haemost 2007 5 (3) 528-534
26. Antovic A, Blombäck M, Bremme K, He S. The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism. Blood Coagul Fibrinolysis 2002 13 (3) 181-186
27. Vedin J, Antovic A, Ericsson A, Vaage J. Hemostasis in off-pump compared to on-pump coronary artery bypass grafting: a prospective, randomized study. Ann Thorac Surg 2005 80 (2) 586-593
28. Viintin Cuderman T, Boi M, Antovic A, Peternel P, Stegnar M. Overall haemostasis potential in patients with venous thrombosis before, during and after anticoagulant treatment. Poster presented at: XXI Congress of the International Society on Thrombosis and Haemostasis 2007 Geneva, Switzerland
29. Morel-Kopp M C., Curnow J, Aboud M, Coyle L, Ward C M. Discrepancies between the overall coagulation potential (OCP) assay and international normalised ratio (INR) in warfarin treated patients. Poster presented at: XX Congress of the International Society on Thrombosis and Haemostasis 2005 Sidney, Australia
30. Antovic J P., Antovic A, He S, Tengborn L, Blombäck M. Overall haemostatic potential can be used for estimation of thrombin activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to FVIII. Haemophilia 2002 8 (6) 781-586
31. Antovic J P., Antovic A. Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay. Thromb Haemost 2003 90 (4) 620-627
32. Kramkowski K, Mogielnicki A, Chabielska E, Cylwik D, Buczko W. The effect of tissue and plasma angiotensin converting enzyme inhibitors on overall haemostatic potentials in rats. Thromb Res 2006 117 (5) 557-561
33. Mogielnicki A, Chabielska E, Pawlak R, Szemraj J, Buczko W. Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost 2005 93 (6) 1069-1076
34. Chabielska E, Mogielnicki A, Kramkowski K, Buczko W. Antithrombotic effect of captopril and enalapril in old rats. Pharmacol Rep 2005 57 (1) 135-137
35. Goldenberg N A., Hathaway W E., Jacobson L, Manco-Johnson M J. A new global assay of coagulation and fibrinolysis. Thromb Res 2005 116 (4) 345-356
36. He S, Zhu K, Skeppholm M et al. A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma. Thromb Haemost 2007 98 (4) 871-882